BNTX
BioNTech SE
Next earnings Aug 4, 2026 · consensus $-1.97 EPS, $216M rev
$97.55
▲ +3.49%$97.55▼ -8.60%
over 1Y
L $83.89H $119.34
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.5%
1W+8.4%
1M+9.4%
3M+7.0%
YTD+0.9%
1Y-8.6%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 26 analysts
Buy
Mixed signals in the latest filings.
BioNTech SE shows limited reported revenue.
On these fundamentals, BNTX screens as SELL on the SEC figures.
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 10:20 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$24.7B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗3Period ending 2026-06-262026-06-26open ↗3Period ending 2026-06-262026-06-26open ↗6-KPeriod ending 2026-06-082026-06-08open ↗6-KPeriod ending 2026-06-012026-06-01open ↗6-KPeriod ending 2026-05-222026-05-22open ↗6-KPeriod ending 2026-05-152026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗4Period ending 2026-05-122026-05-13open ↗4Period ending 2026-05-122026-05-13open ↗4Period ending 2026-05-122026-05-13open ↗4Period ending 2026-05-122026-05-13open ↗
Frequently asked
- Is BioNTech SE (BNTX) a buy?
- BNTX currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is BioNTech SE's quality score?
- BNTX scores 50.44837000679631/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001776985, latest 3 filed 2026-06-26) · EODHD · as of 7/4/2026, 2:20:10 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.